Two new drug treatments for HER2-positive breast cancer were tested in separate studies. One study involves the drug Tucatinib, and the other involves an antibody-drug called trastuzumab deruxtecan.
Study illuminates circadian rhythms, disorders with seasonal flare-ups
AIDS expert explains why he is cautiously optimistic about the promising trial results of the drug lenacapavir.
Award helps basic researchers and physician-scientists pursue their boldest ideas
New Harvard-led research links irregular sleeping patterns with a heightened risk of developing the disease.
Cell biologist embraces new tools to study human development on the smallest scale
As patients themselves, they’re shaping the doctors they want to be and to have
In a collaboration between investigators at the Harvard Kennedy School, Harvard Chan School of Public Health, and Georgetown University, groundbreaking research shows that experiencing gratitude…
Researchers used neural activity to understand how the human brain represents the words it hears
Researchers outline path to lower risk of depression
New director shares vision for Office for Community-Centered Medical Education
